Mergers & Acquisitions ·
Sanara MedTech Inc. entered into a definitive Agreement and Plan of Merger with MiMedx Group, Inc., under which MiMedx…
SMTISanara MedTech Inc.
Sanara MedTech Inc. entered into a definitive Agreement and Plan of Merger with MiMedx Group, Inc., under which MiMedx will acquire Sanara in an all-stock and cash transaction valued at approximately $350 million. Each outstanding share of Sanara common stock will be converted into the right to receive $33.00 in cash and 0.4735 shares of MiMedx common stock, representing a total consideration of $35 per share. This mix includes a cash component and a stock component valued at $2.00 per share based on MiMedx's five-day average closing price. The Sanara Board unanimously recommended the transaction, which is expected to close by the end of 2026 subject to shareholder approval, regulatory clearances including Hart-Scott-Rodino, and other customary conditions. MiMedx intends to finance the cash portion using existing cash and a new $300 million term loan from Hayfin Capital Management. The combined entity is projected to generate over $400 million in 2027 revenue with an adjusted EBITDA margin exceeding 20%. Sanara MedTech Inc. operates in the medical technology industry, developing and commercializing regenerative products for surgical markets.